Abstract:
본 발명은 단일불포화 디니트릴 중간체 화합물을 거치는, 천연 단일불포화 지방산으로부터의 ω-아미노알칸산 또는 이의 에스테르의 합성 방법에 관한 것이다. 본 발명의 방법은 공지된 다른 방법에 비해 수행하기가 단순하고, 반응 부산물로 인한 환경 제약조건 및 경제적 단점을 회피한다.
Abstract:
There is provided a copolymer having the general structure below, wherein a, b, and d are molar ratios varying between about 0.01 and about 0.90 and c is a molar ratio varying between about 0,01 and about 0.90; A1 represents monomer units comprising a cyano-containing pendant group in which the cyano is not directly attached to the backbone of the copolymer; A2 represents monomer units comprising two or more hydrogen bonding sites; A3 represents monomer units that increase solubility in organic solvents; and A4 represents monomer units that increase solubility in aqueous alkaline solutions. There is also provided a near-infrared radiation-sensitive coating composition comprising this copolymer as well as a positive-working thermal lithographic printing plate comprising a near-infrared radiation-sensitive coating comprising this copolymer, a method of producing such a printing plate, and finally a method of printing using such a printing plate. Formula (I)
Abstract:
본 발명은 프로키랄 올레핀의 거울상 이성질체 선택적인 수소화를 통해 (S)-(+)-3-(아미노메틸)-5-메틸헥산산 및 이에 구조적으로 관련된 화합물을 제조하기 위한 물질 및 방법에 관한 것이다. 이 방법에서는 신규의 키랄 촉매를 사용하는데, 이 촉매는 전이금속에 결합된 C 1 -대칭 비스포스핀 리간드를 포함한다.
Abstract:
One aspect of the present invention relates to quinine-based and quinidine-based catalysts. Another aspect of the invention relates to a method of preparing a derivatized quinine-based or quinidine-based catalyst comprising 1) reacting quinine or quinidine with 5 base and a compound that has a suitable leaving group, and 2) converting the ring methoxy group to a hydroxy group. Another aspect of the present invention relates to a method of preparing a chiral, non-racemic compound from a prochiral electron-deficient alkene or azo compound or prochiral aldehyde or prochiral ketone, comprising the step of: reacting a prochiral electron-deficient alkene or azo compound or prochiral aldehyde or prochiral 10 ketone with a nucleophile in the presence of a catalyst; thereby producing a chiral, non racemic compound; wherein said catalyst is a derivatized quinine or quinidine. Another aspect of the present invention relates to a method of kinetic resolution, comprising the step of reacting racemic chiral alkene with a nucleophile in the presence of a derivatized quinine or quinidine. ® KIPO & WIPO 2007
Abstract:
PURPOSE: Provided is a method for preparing an organic compound having a halogen atom combined with the carbon atom bonded by four σ-bondings whose halogen atom is substituted with a substituent derived from a nucleophilic agent in a high yield. CONSTITUTION: The method comprises the step of reacting a compound represented by MQa and an organic compound having a halogen atom combined with the carbon atom bonded by four σ-bondings as a halogen atom in the presence of a compound represented by the formula 1, to substitute at least one halogen atom of the organic compound with Q, wherein Z- is an anion derived by removing a proton from an inorganic acid or an active hydrogen compound; all Rs are identical or different one another, and are independently a C1-C10 hydrocarbon group or can form a ring together with a nitrogen atom by the combination of two Rs on the same nitrogen atom; M is an alkali metal, an alkaline earth metal or a rare earth metal; Q is a group derived by removing a proton from an inorganic acid or an active hydrogen compound, but is not a halogen atom identical with the halogen atom of the organic compound to be substituted with Q; and a is an integer of 1-3.
Abstract:
본 발명은 세포 접착 및 세포 접착-매개 병변의 억제 및 예방에 유용한 신규 화합물에 관한 것이다. 본 발명은 또한 이들 화합물을 포함하는 약학 제제 및 이들 제제를 세포 접착 및 세포 접착-매개 병변의 억제 및 예방에 사용하는 방법에 관한 것이기도 하다. 상기 본 발명의 화합물 및 약학 조성물은 치료 또는 예방 제제로서 사용할 수 있다. 이들은 특히 많은 염증 및 지가면역 질환의 치료에 적합하다.
Abstract:
Process for the carbonylation of ethylenically unsaturated compounds having 3 or more carbon atoms by reaction with carbon monoxide and an hydroxyl group containing compound in the presence of a catalyst system. The catalyst system includes (a) a source of palladium cations; (b) a bidentate diphosphine of formula (I): R1R2 > P - R3 - R - R4 -P